Sugi Predict

Sugi Predict / Compounds / SCHEMBL371931

SCHEMBL371931

SCHEMBL371931

COc1cc2ncnc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3F)c2cc1OCC1CCN(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 10/20 0.51
▸ MET P08581 3/20 0.51
▸ EGFR P00533 11/20 0.50
▸ KIT P10721 4/20 0.48
▸ RAF1 P04049 1/20 0.46
▸ RET P07949 2/20 0.46
▸ KIF5B P33176 2/20 0.46
▸ FGFR1 P11362 7/20 0.46
▸ FLT1 P17948 7/20 0.46
▸ FLT4 P35916 7/20 0.46
▸ PDGFRB P09619 2/20 0.46
▸ TEK Q02763 2/20 0.46
▸ BMPR1B O00238 1/20 0.46
▸ PLK4 O00444 1/20 0.46
▸ CIT O14578 1/20 0.46
▸ GAK O14976 1/20 0.46
▸ EPHB6 O15197 1/20 0.46
▸ RIPK2 O43353 1/20 0.46
▸ ROCK2 O75116 1/20 0.46
▸ STK10 O94804 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371976 1.00 KDR (0.51) KDRMETEGFRKITRAF1
SCHEMBL15090669 0.91 MET (0.48) KDRMETEGFRKITRAF1
SCHEMBL15061166 0.91 MET (0.49) KDRMETEGFRKITRET
SCHEMBL372086 0.91 MET (0.53) KDRMETEGFRKITRAF1
SCHEMBL409483 0.89 MET (0.62) KDRMETEGFRKITRET
SCHEMBL371717 0.85 KDR (0.52) KDRMETEGFRKITRAF1
SCHEMBL371948 0.84 MET (0.57) KDRMETEGFRKITRAF1
SCHEMBL372133 0.84 MET (0.57) KDRMETEGFRKITRAF1
SCHEMBL372147 0.83 MET (0.52) KDRMETEGFRKITRAF1
SCHEMBL407471 0.82 AXL (0.46) KDRMETEGFRKITRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120184523-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-07-19 — — US claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 — — US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885MET 3/4885EGFR 124/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET KDR 4/4885MET 3/4885EGFR 124/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885MET 3/4885EGFR 124/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885MET 3/4885EGFR 124/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET KDR 4/4885MET 3/4885EGFR 124/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS KDR 1023/4885MET 312/4885EGFR 60/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 KDR 5/4885MET 2/4885EGFR 166/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KDR 5/4885MET 2/4885EGFR 181/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KDR 5/4885MET 2/4885EGFR 181/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET KDR 4/4885MET 3/4885EGFR 124/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 KDR 5/4885MET 2/4885EGFR 166/4885
US-20120184523-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 KDR 5/4885MET 2/4885EGFR 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.